Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Leases: 2015-2019

Historic Capital Leases for Enanta Pharmaceuticals (ENTA) over the last 5 years, with Sep 2019 value amounting to $200,000.

  • Enanta Pharmaceuticals' Capital Leases fell 31.74% to $200,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $200,000, marking a year-over-year decrease of 31.74%. This contributed to the annual value of $200,000 for FY2019, which is 31.74% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Capital Leases stood at $200,000 for Q3 2019, which was down 10.71% from $224,000 recorded in Q2 2019.
  • Enanta Pharmaceuticals' 5-year Capital Leases high stood at $529,000 for Q3 2015, and its period low was $175,000 during Q2 2015.
  • Its 3-year average for Capital Leases is $313,545, with a median of $315,000 in 2018.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Capital Leases soared by 173.14% in 2016 and then crashed by 31.74% in 2019.
  • Over the past 5 years, Enanta Pharmaceuticals' Capital Leases (Quarterly) stood at $513,000 in 2015, then fell by 14.23% to $440,000 in 2016, then dropped by 18.64% to $358,000 in 2017, then decreased by 24.30% to $271,000 in 2018, then slumped by 31.74% to $200,000 in 2019.
  • Its Capital Leases stands at $200,000 for Q3 2019, versus $224,000 for Q2 2019 and $249,000 for Q1 2019.